Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV
Conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma; HIV-1-infection; HPV Infection Interventions: Biological: 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58); Other: Saline Placebo Sponsors: Weill Medical College of Cornell University; H. Lee Moffitt Cancer Center and Research Institute; University of Sao Paulo; University of Puerto Rico; Mexican National Institute of Public Health; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cervical Cancer Vaccine | Gardasil | Genital Warts | Human Papillomavirus (HPV) | Oral Cancer | Oropharyngeal Cancer | Research | Skin Cancer | Squamous Cell Carcinoma | Vaccines